Efficacy of Diethylcarbamazine in Allergic Rhinitis as an Adjuvant to Antihistamines : A Comparative Study
Background: Allergic rhinitis is a type of inflammation in the nose that occurs when the immune system overreacts to allergens in the air. Underlying mechanism involves IgE antibodies that attach to allergen resulting in release of histamine from mast cells. Signs and symptoms include a runny or stuffy nose, sneezing, redness and watering of eyes. Symptom onset is often within minutes following allergen exposure and can affect sleep and ability to work or study. People with allergic rhinitis may have associated asthma, allergic conjunctivitis, atopic dermatitis. The study aims to know the efficacy of diethyl carbamazine in reducing the severity of symptoms in patients with allergic rhinitis when added to the antihistaminic treatment. Methods: This is a single blind randomized control trial study involving 50 allergic rhinitis patients between 13-60 years as cases and 50 as controls. The patients were classified as mild, moderate and severe based on the severity of symptoms. The cases were prescribed Tablet Diethyl carbamazine 300mg along with Tablet cetrizine 10mg for a period of 21 days. The controls were prescribed Tablet cetrizine 10mg with placebo. Patients were followed up for 3 months and watched for any reduction in the severity of symptoms. Results were compared between the study and control groups. Results: Out of 50 patients in the study group, 20 cases showed improvement, 30 cases did not show any improvement; Out of 50 controls, 6 showed improvement and 44 didn’t show any improvement. P value is significant (0.003). Conclusion: Diethyl carbamazine is an ant filarial drug which is found to have an effect in reducing the mediators of inflammation thereby useful in reducing the severity of symptoms in allergic rhinitis, as an adjuvant.
2. Barnes PJ. Pathophysiology of allergic inflammation. Immunol Rev 2011;242(1):31-50.
3. Schmidt CW. Pollen Overload: Seasonal Allergies in a Changing Climate. Environ Health Perspect 2016;124(4):A70-5.
4. Dold S, Wjst M, von Mutius E, Reitmeir P, Stiepel E. Genetic risk for asthma, allergic rhinitis, and atopic dermatitis. Arch Dis Child 1992;67(8):1018-22.
5. Adinarayanan S, Critchley J, Das PK, Gelband H. Diethylcarbamazine (DEC)-medicated salt for community-based control of lymphatic filariasis. Cochrane Database Syst Rev 2007;2007(1):CD003758.
6. Valero A, Del Cuvillo A, Navarro AM, Colás C, Sastre J, Mullol J.Validation of the ARIA items to assess allergic rhinitis control (ARIA-C). Allergy 2020;10.1111/all.14418
7. Mullerpattan JB, Udwadia ZF, Udwadia FE. Tropical pulmonary eosinophilia--a review. Indian J Med Res 2013;138(3):295-302.
8. Klimek L, Bergmann KC, Biedermann T, et al. Visual analogue scales (VAS): Measuring instruments for the documentation of symptoms and therapy monitoring in cases of allergic rhinitis in everyday health care: Position Paper of the German Society of Allergology (AeDA) and the German Society of Allergy and Clinical Immunology (DGAKI), ENT Section, in collaboration with the working group on Clinical Immunology, Allergology and Environmental Medicine of the German Society of Otorhinolaryngology, Head and Neck Surgery (DGHNOKHC). Allergo J Int 2017;26(1):16-24.
9. Pawankar R, Mori S, Ozu C, Kimura S. Overview on the pathomechanisms of allergic rhinitis. Asia Pac Allergy 2011;1(3):157-67.
10. Min YG. The pathophysiology, diagnosis and treatment of allergic rhinitis. Allergy Asthma Immunol Res 2010;2(2):65-76.
11. McGarry HF, Plant LD, Taylor MJ. Diethylcarbamazine activity against Brugia malayi microfilariae is dependent on inducible nitric-oxide synthase and the cyclooxygenase pathway. Filaria J 2005;4:4.
|Issue||Vol 10, No 2 (Spring 2022)|
|Allergic Rhinitis Diethyl Carbamazine Antihistamines|
|Rights and permissions|
|This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.|